WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Study of Hydroxychloroquine: A Comprehensive Review and its Controversial Role in Coronavirus Disease 2019

Ratnesh Singh[1], Dr. Vishwadeepak Kimothi[2]

[1]Master of Pharmacy (Pharmacology), Himalayan Institute of Pharmacy & Research, Dehradun
[2]**Supervisor,** Himalayan Institute of Pharmacy & Research, Dehradun

Executive Summary

Hydroxychloroquine (HCQ), an antimalarial and immunomodulatory drug, became the focus of global attention during the COVID-19 pandemic due to its proposed antiviral properties. This 30-page summary critically reviews HCQ's pharmacology, traditional medical applications, rapid adoption in COVID-19 treatment, major clinical trials, ethical dilemmas, regulatory actions, and future implications for pandemic preparedness.

1. Introduction

HCQ, a 4-aminoquinoline compound, has been a cornerstone treatment in malaria and autoimmune diseases like SLE and RA. The onset of COVID-19 transformed HCQ from a niche therapy to a widely publicized potential cure, driven more by urgency and politics than by scientific validation.

2. Pharmacological Overview

Chemical Structure: Weak base, accumulates in acidic vesicles. **Mechanism of Action:**

- Raises endosomal pH.
- Inhibits antigen processing.
- Suppresses toll-like receptor (TLR) activity. **Pharmacokinetics:**
- Long half-life (40–50 days).
- Hepatic metabolism.
- Renal excretion. **Toxicity:** QT prolongation, retinal toxicity, hypoglycemia.

3. Medical Applications Pre-COVID

Malaria: Effective against chloroquine-sensitive strains. **Autoimmune Diseases:**

- **SLE:** Prevents flares, improves survival.
- **RA:** Reduces inflammation and joint damage.
- **Other Conditions:** Sjögren's, dermatomyositis, cutaneous lupus.

4. HCQ in the COVID-19 Pandemic

4.1 Early Hype

Initial lab studies suggested antiviral properties. A controversial French study catalyzed widespread, often unauthorized, use. Emergency Use Authorizations (EUAs) followed in countries like the USA and India.

4.2 Global Timeline

- **Jan 2020:** In vitro success reported.
- **Mar 2020:** FDA issues EUA.
- **Jun 2020:** WHO halts SOLIDARITY trial HCQ arm.
- **Jul 2020:** FDA revokes EUA.

5. Major Clinical Trials

RECOVERY (UK): No mortality benefit.

SOLIDARITY (WHO): No significant impact; study halted.

ICMR (India): Mild prophylactic effects, insufficient data.

ORCHID (NIH): No improvement in clinical outcomes.

6. Regulatory Decisions and Reversals

- WHO: Stopped trials mid-way.
- FDA: Revoked EUA after emerging safety data.
- ICMR: Continued limited recommendation despite global rejection.

7. Ethical Issues

7.1 Scientific Misconduct

- Preprint misuse.
- Non-peer-reviewed studies influencing global health policy.
- Surgisphere scandal: Data manipulation.

7.2 Emergency Approvals

- Bypassed full review protocols.
- Lacked informed consent in some trials.

7.3 Political Interference

- Politicians endorsed HCQ without scientific backing.
- Resulted in hoarding, misuse, and public confusion.

8. Media, Misinformation, and Public Harm

- Widespread misinformation led to poisoning and overdoses.
- Legitimate patients faced drug shortages.
- Lack of centralized communication exacerbated panic.

9. Health Inequities and Global Disparities

- Stockpiling by high-income countries.
- Poor regulatory oversight in low-income regions.
- Overrepresentation of vulnerable populations in trials.

10. Lessons Learned

Ethical Challenge	Recommended Solution
Misuse of EUA	Transparent evidence grading system
Informed Consent Issues	Pandemic-specific ethics review protocols
Political Influence	Independent scientific advisory boards
Misinformation Spread	National science communication taskforces
Inequitable Access	WHO-led drug distribution and trial coordination

11. Future Recommendations

1. **Drug Approval:** Implement staged approval models with regular reviews.
2. **Research Ethics:** Enforce community-inclusive informed consent processes.
3. **Public Communication:** Launch multilingual, multimedia campaigns.
4. **Global Coordination:** WHO must lead equitable access and trial transparency.
5. **AI Integration:** Use AI to predict repurposing potential responsibly.

12. Conclusion

Hydroxychloroquine's pandemic journey serves as a case study in crisis-driven science, highlighting the dangers of political overreach, media sensationalism, and premature endorsements. The future of pandemic pharmacology must prioritize robust evidence, ethical integrity, and equitable global frameworks. Only then can science reclaim its role as the primary navigator in global health emergencies.